A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters
Description
Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform. In reality, however, differences in the plant biosynthetic machinery, compared to mammalian cells, can complicate the production of viral glycoproteins
